Brokerages Set Bausch + Lomb Corporation (NYSE:BLCO) Target Price at $17.42

Shares of Bausch + Lomb Corporation (NYSE:BLCO) have been assigned a consensus rating of “Hold” from the fifteen analysts that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $17.4167.

A number of research firms have issued reports on BLCO. Evercore set a $18.00 target price on shares of Bausch + Lomb and gave the company an “in-line” rating in a research report on Monday, January 5th. Wall Street Zen raised shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. JPMorgan Chase & Co. raised their price objective on shares of Bausch + Lomb from $13.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Barclays upped their target price on shares of Bausch + Lomb from $16.00 to $17.00 and gave the company an “equal weight” rating in a research report on Friday, October 31st. Finally, Raymond James Financial reissued an “outperform” rating and issued a $19.00 price target (up previously from $18.00) on shares of Bausch + Lomb in a research note on Thursday, October 30th.

Bausch + Lomb Stock Down 0.6%

NYSE BLCO opened at $17.05 on Monday. The stock has a market capitalization of $6.04 billion, a P/E ratio of -19.59, a price-to-earnings-growth ratio of 1.00 and a beta of 0.61. Bausch + Lomb has a 52 week low of $10.45 and a 52 week high of $17.86. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.98 and a current ratio of 1.51. The stock has a fifty day moving average of $16.98 and a 200-day moving average of $15.70.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Oaktree Capital Management LP boosted its holdings in shares of Bausch + Lomb by 28.7% in the third quarter. Oaktree Capital Management LP now owns 3,245,439 shares of the company’s stock valued at $48,909,000 after buying an additional 724,194 shares during the period. Goldentree Asset Management LP boosted its stake in Bausch + Lomb by 3.0% in the 3rd quarter. Goldentree Asset Management LP now owns 2,660,508 shares of the company’s stock worth $40,002,000 after purchasing an additional 77,323 shares during the period. Glenview Capital Management LLC boosted its stake in Bausch + Lomb by 210.8% in the 2nd quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock worth $20,216,000 after purchasing an additional 1,053,855 shares during the period. Compass Rose Asset Management LP increased its holdings in Bausch + Lomb by 22.0% during the 3rd quarter. Compass Rose Asset Management LP now owns 1,000,000 shares of the company’s stock worth $15,070,000 after purchasing an additional 180,000 shares in the last quarter. Finally, Davidson Kempner Capital Management LP acquired a new stake in shares of Bausch + Lomb in the 3rd quarter valued at about $14,776,000. 11.07% of the stock is currently owned by institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.